Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05613764 · ClinicalTrials.gov registry record · NA

Message From Local Pharmacy Team

A NA study of COVID-19, sponsored by University of Pennsylvania.

Completed
Registry status
NA
Development phase
520,000
Enrollment target
1
Study location

NCT05613764 is a NA study of COVID-19 that has completed, run by University of Pennsylvania. The registered enrollment target is 520,000 participants, above the 52,653-participant average among 203 other COVID-19 trials with a reported enrollment target (888% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05613764, a NA study of COVID-19, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
NA
Development phase
520,000 participants
Enrollment target
1
Study location

Study Summary

This experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned. The focal comparison in this experiment is between a message encouraging vaccination that comes from a patient's local pharmacy team and a control message telling patients that an updated COVID booster vaccine is waiting for them. The intervention testing if text messages encouraging vaccination that come from a patient's local pharmacy team will produce more vaccinations than otherwise identical messages.

Conditions Studied

Interventions

  • BEHAVIORAL COVID Booster text messages

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 520,000 participants
Start Date 2022-11-03
Est. Completion 2023-02-06
Phase NA

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT05613764

The ClinicalTrials.gov registry entry for NCT05613764 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 520,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 52,653-participant average among 203 other COVID-19 trials with a reported enrollment target (888% higher). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which COVID Booster text messages is the first listed.

NCT05613764 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05613764 about?

NCT05613764 is a clinical study titled "Message From Local Pharmacy Team". This experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned. The focal comparison in this experiment is between a message encouraging vaccination that comes from a patient's local pharmacy team and a c...

What is the current status of trial NCT05613764?

This trial is currently completed. It is a NA study. The enrollment target is 520,000 participants. The study started on 2022-11-03. Estimated completion is 2023-02-06.

What conditions does trial NCT05613764 study?

This clinical trial studies the following conditions: COVID-19.

What interventions are being tested in trial NCT05613764?

The interventions under investigation include: COVID Booster text messages (BEHAVIORAL).

Who is sponsoring clinical trial NCT05613764?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05613764 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.